News | October 07, 2009

New Instructions Released for April FDG-PET NCD Changes

October 7, 2009 - CMS recently released to the Medicare Administrative Contractors (MACs), via transmittals 1817 and 106, reissued Guidance and Billing Instructions for the April 2009 changes to the National Coverage Determination (NCD) on Positron Emission Tomography (FDG).

Providers will have two new modifiers (in addition to the list of current modifiers) to consider when submitting claims with a date of service (DOS) on or after April 6, 2009 for CPT codes 78608, 78811-78816 for oncologic procedures.

Available on or after the implementation date of October 19, 2009, providers submitting claims with a DOS on or after April 6, 2009 for CPT codes 78608, 78811-78816 are now required to identify the procedure as either for initial treatment strategy or subsequent treatment strategy by appending the modifiers PI or PS, respectively.

CMS removed the previously identified ICD-9 range of codes allowing discretion at the local level with the Medicare Contractors. CMS did identify the combination of PI and ICD-9 codes that are newly non-covered 185 for adenocarcinoma of prostate.

Providers participating in the national oncologic PET registry (NOPR) for those procedures which continue to be covered only under coverage with evidence development (CED) continue to use the Q0 (zero) modifier and/or V70.7 in the second diagnosis position with condition code 30 in addition to using one of the two new modifiers below.

New Modifiers for PET Effective for Dates of Services (DOS) on or after April 6, 2009 Implemented on or after October 19, 2009

PI – Positron Emission Tomography (PET) or PET/Computed Tomography (CT) to inform the initial treatment strategy of tumors that are biopsy proven or strongly suspected of being cancerous based on other diagnostic testing. Short descriptor: PET tumor init tx strat

PS – Positron Emission Tomography (PET) or PET/Computed Tomography (CT) to inform the subsequent treatment strategy of cancerous tumors when the beneficiary's treating physician determines that the PET study is needed to inform subsequent anti-tumor strategy. Short descriptor: PET tumor subsq tx strategy

MACs have until October 19, 2009 to implement these changes in their systems. PET facilities will likely have similar transition time. Continue to submit your claims in accordance with past instructions until your local contractor issues local instructions and implementation date.

For more information: cms.hhs.gov

Related Content

International Working Group Releases New Multiple Myeloma Imaging Guidelines

X-ray images such as the one on the left fail to indicate many cases of advanced bone destruction caused by multiple myeloma, says the author of new guidelines on imaging for patients with myeloma and related disorders. Image courtesy of Roswell Park Comprehensive Cancer Center.

News | Computed Tomography (CT) | June 17, 2019
An International Myeloma Working Group (IMWG) has developed the first set of new recommendations in 10 years for...
A high-fidelity 3-D tractography of the left ventricle heart muscle fibers of a mouse

Figure 1. A high-fidelity 3-D tractography of the left ventricle heart muscle fibers of a mouse from Amsterdam Ph.D. researcher Gustav Strijkers.

News | Magnetic Resonance Imaging (MRI) | June 07, 2019
The Amsterdam University Medical Center has won MR Solutions’ Image of the Year 2019 award for the best molecular...
BGN Technologies Introduces Novel Medical Imaging Radioisotope Production Method
News | Radiopharmaceuticals and Tracers | June 05, 2019
BGN Technologies, the technology transfer company of Ben-Gurion University (BGU), introduced a novel method for...
RefleXion Opens New Manufacturing Facility for Biology-guided Radiotherapy Platform
News | Radiation Therapy | May 31, 2019
RefleXion Medical recently announced the opening of its new manufacturing facility at its headquarters in Hayward,...
Study Explores Magnetic Nanoparticles as Bimodal Imaging Agent for PET/MRI

Image courtesy of MR Solutions.

News | PET-MRI | May 23, 2019
Researchers from Bourgogne University in Dijon, France, showed that use of superparamagnetic iron oxide nanoparticles (...
New Phase 2B Trial Exploring Target-Specific Myocardial Ischemia Imaging Agent
News | Radiopharmaceuticals and Tracers | May 17, 2019
Biopharmaceutical company CellPoint plans to begin patient recruitment for its Phase 2b cardiovascular imaging study in...
Blue Earth Diagnostics Expands Access to Axumin in Europe
News | Radiopharmaceuticals and Tracers | May 13, 2019
Blue Earth Diagnostics announced expanded access to the Axumin (fluciclovine (18F)) imaging agent in Europe. The first...
NIH Study of Brain Energy Patterns Provides New Insights into Alcohol Effects

NIH scientists present a new method for combining measures of brain activity (left) and glucose consumption (right) to study regional specialization and to better understand the effects of alcohol on the human brain. Image courtesy of Ehsan Shokri-Kojori, Ph.D., of NIAAA.

News | Neuro Imaging | March 22, 2019
March 22, 2019 — Assessing the patterns of energy use and neuronal activity simultaneously in the human brain improve